Compare BFS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | CGEM |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.2M | 671.7M |
| IPO Year | 1993 | 2021 |
| Metric | BFS | CGEM |
|---|---|---|
| Price | $31.94 | $10.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 75.9K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $282,618,000.00 | N/A |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | $27.99 | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $29.16 | $5.68 |
| 52 Week High | $40.47 | $13.33 |
| Indicator | BFS | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 47.45 |
| Support Level | $31.42 | $9.48 |
| Resistance Level | $32.45 | $13.10 |
| Average True Range (ATR) | 0.59 | 0.98 |
| MACD | 0.16 | -0.31 |
| Stochastic Oscillator | 80.99 | 13.26 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.